Histogen is a regenerative medicine company with multiple product candidates in clinical development intended to address what Histogen believes to be underserved, multibillion dollar global markets. The Company’s patented technology focuses on replacing and regenerating tissues in the body with materials that have been shown to support human cell growth and differentiation. Histogen’s technology has potential therapeutic benefit in multiple treatment settings to include skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers.

Histogen has raised $38M in equity, the majority of which has been used to develop and optimize its proprietary manufacturing process, submit patents in a number of countries, and refine and advance its product candidates. The Company intends to build on previous clinical experience through completion of U.S. clinical trials of its hair growth, joint cartilage and dermal filler products in 2020 and 2021.

On February 11, 2020 Chairman and CEO Richard Pascoe presented an overview of Histogen’s technology and development pipeline during the BIO CEO & Investor Conference. The presentation is available for review here.

For more information about investment opportunities please contact:

Susan A. Knudson
Executive Vice President & CFO


Market Highlights:

According to our research, $3.6 billion is spent on hair loss in the U.S., with limited treatment options currently available

1.2 million patients receive dermal fillers in the U.S., a market that is continuing to see rapid growth

17.5 million patients are considering joint cartilage repair, and no currently available treatments regenerate hyaline cartilage